Breaking News
Food Shortages In 2027? The ICC Warns That Global Food Prices Could Rise By Close To 70%
Interview 2039 - The "Rogue AI" Psyop on the IMA Roundtable
Federal Survey Of 21,990 Kids Ties COVID Shots To Autism, ADHD
AI Geniuses Are Decidedly Not Policy And Economic Geniuses
Top Tech News
SHOCK CASE REPORT: Advanced Alzheimer's Patient Regains Speech, Memory, Mobility...
Most artificial limbs rely on silicone or plastic to mimic human hands.
Flying cell tower beams phone signal to Japan from 10 miles up
Chinese Commercial Reactor Achieves Nuclear Fusion with Clean Hydrogen-Boron Fuel
Med Beds Just Took a MASSIVE Step Forward, Healing People in Days!
Palmer Luckey: Autonomous Weapons Are Ancient and Why Anduril Won't Build Humanoids | EP #295
A laser just photographed objects through six feet of concrete
Elon Musk's Next-Gen Motor Destroy Entire EV Industry
China's disputed satellite refueling heralds new space war era
BYD Will Put Solid-State Batteries In An EV Next Year: Executive
Sanofi Made False Claims About RSV Shot for Infants, FDA Says
In a letter to the drugmaker, the FDA said the agency approved Beyfortus, an RSV monoclonal antibody, as a defense against RSV lower respiratory tract disease — but that Sanofi has been claiming it protects broadly against RSV disease, which occurs in the lower and upper tracts. Beyfortus has come under scrutiny following reports of at least two infant deaths during clinical trials for the drug.
The U.S. Food and Drug Administration (FDA) is accusing Sanofi of making false or misleading promotional claims about Beyfortus, a preventative treatment for RSV, Fierce Pharma reported.
In a letter to the drugmaker, the FDA said it approved Beyfortus specifically as a defense against respiratory syncytial virus (RSV) lower respiratory tract disease — but that Sanofi has been claiming it protects broadly against RSV disease, which occurs in the lower and upper tracts.
The company has sent providers emails urging them to give the shot to "help prevent RSV disease in infants."
The promotional materials included other similar statements, including, "Beyfortus is a monoclonal antibody that helps prevent RSV disease starting from Day 1 after injection," and "Your efforts in immunizing infants against RSV disease can impact the population health burden in your community."